Skip to main content
Equibles

Hervé Hoppenot

Board Member

Maze Therapeutics, Inc. (MAZE)

Chairman

Maze Therapeutics, Inc. (MAZE)

Equibles does not estimate personal net worth.

Get an email with a short summary when Maze Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get MAZE alerts

About Hervé Hoppenot

Hervé Hoppenot is recorded as Board Member at Maze Therapeutics, Inc. (MAZE) since August 13, 2026 and Chairman at Maze Therapeutics, Inc. (MAZE) since October 6, 2025. Maze Therapeutics, Inc. reported in an 8-K filed August 17, 2026 that Hervé Hoppenot was appointed Class III director, effective August 13, 2026. Maze Therapeutics, Inc. reported in an 8-K filed August 17, 2026 that Hervé Hoppenot resigned as Class II director, effective August 13, 2026. Maze Therapeutics, Inc. reported in an 8-K filed October 6, 2025 that Hervé Hoppenot was appointed Class II director, effective October 6, 2025. Equibles holds 4 filed executive changes naming Hervé Hoppenot; each is listed under recent activity with its source filing. Maze Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Maze Therapeutics, Inc. includes Jason Coloma (CEO and Board Member), Misbah Tahir (CFO), Courtney Phillips (General Counsel) and 7 others.

“the Board accepted Mr. Hoppenot's resignation and immediately reappointed him as a Class III director with a term expiring at the Company's 2028 annual meeting of stockholders.”
Maze Therapeutics, Inc. Form 8-K, filed August 17, 2026 · Read the filing
“Also effective August 13, 2026, Hervé Hoppenot resigned from his position as a Class II director (with a term expiring at the Company's 2027 annual meeting of stockholders), subject to and conditioned upon his immediate reappointment as a Class III director, and the Board accepted Mr. Hoppenot's resignation and immediately reappointed him as a Class III director with a term expiring at the Company's 2028 annual meeting of stockholders.”
Maze Therapeutics, Inc. Form 8-K, filed August 17, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at Maze Therapeutics, Inc.

Recent activity